Autologous growth factor and cellular receptors

The term "Unknown / heterogeneous endogenous receptors for autologous growth factors and cells" refers to a broad pharmacological category used to describe the collective action of autologous biological therapies [1]. These therapies, including platelet-rich plasma (PRP) and autologous conditioned serum, function by delivering a concentrated cocktail of endogenous ligands—such as Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-beta (TGF-β)—to their respective cell-surface receptors [2]. Upon activation, these receptors trigger essential intracellular signaling pathways, including the MAPK and PI3K/Akt cascades, which drive cellular proliferation, angiogenesis, and tissue regeneration [3]. This multi-target mechanism is primarily utilized in regenerative medicine for treating musculoskeletal injuries, chronic wounds, and degenerative joint diseases [4]. Because the therapy relies on the patient's own biological material, it engages a wide array of receptors across various cell types to facilitate a synergistic healing response [5]. However, the lack of a single, well-defined molecular target presents significant challenges in standardizing treatment protocols and characterizing precise pharmacodynamic profiles [1][6].

Other names

Unknown / heterogeneous endogenous receptors for autologous growth factors and cellsEndogenous growth factor receptorsAutologous cell therapy targetsPlatelet-rich plasma receptorsAutologous biological targets

Activation of diverse endogenous signaling pathways through the delivery of concentrated autologous ligands to their respective cell-surface receptors to promote tissue repair and modulate inflammation.